MEDNAX (NYSE:MD) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

MEDNAX (NYSE:MDGet Rating) announced its earnings results on Thursday. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.06, MarketWatch Earnings reports. The company had revenue of $482.20 million during the quarter, compared to the consensus estimate of $471.29 million. MEDNAX had a net margin of 6.85% and a return on equity of 15.26%. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 earnings per share.

MD traded down $2.17 during trading on Friday, hitting $18.52. 837,306 shares of the company traded hands, compared to its average volume of 562,930. The firm has a market cap of $1.61 billion, a P/E ratio of 17.31, a price-to-earnings-growth ratio of 1.46 and a beta of 2.06. The stock’s fifty day moving average is $23.22 and its 200 day moving average is $25.14. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 1.12. MEDNAX has a one year low of $18.46 and a one year high of $35.67.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its position in MEDNAX by 198.7% during the second quarter. Royal Bank of Canada now owns 6,192 shares of the company’s stock worth $187,000 after purchasing an additional 4,119 shares during the period. Morgan Stanley boosted its position in MEDNAX by 19.3% during the second quarter. Morgan Stanley now owns 513,145 shares of the company’s stock worth $15,472,000 after purchasing an additional 83,109 shares during the period. Janus Henderson Group PLC bought a new position in MEDNAX during the third quarter worth about $221,000. Credit Suisse AG boosted its position in MEDNAX by 3.9% during the fourth quarter. Credit Suisse AG now owns 70,086 shares of the company’s stock worth $1,906,000 after purchasing an additional 2,645 shares during the period. Finally, Legal & General Group Plc boosted its position in MEDNAX by 3.2% during the fourth quarter. Legal & General Group Plc now owns 245,781 shares of the company’s stock worth $6,688,000 after purchasing an additional 7,561 shares during the period. Institutional investors own 96.99% of the company’s stock.

Several analysts have recently commented on MD shares. Credit Suisse Group lowered their target price on shares of MEDNAX from $32.00 to $31.00 and set an “outperform” rating for the company in a report on Wednesday, February 23rd. StockNews.com started coverage on shares of MEDNAX in a report on Thursday, March 31st. They issued a “buy” rating for the company. TheStreet downgraded shares of MEDNAX from a “b-” rating to a “c+” rating in a report on Wednesday, April 13th. Finally, Zacks Investment Research downgraded shares of MEDNAX from a “buy” rating to a “hold” rating and set a $25.00 target price for the company. in a report on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $29.38.

About MEDNAX (Get Rating)

MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Read More

Earnings History for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.